RMD – UBS rates the stock as Buy

UBS incorporates a 10% share buyback into forecasts, after assuming no major increases in debt levels due to any significant near-term acquisitions. This is calculated to result in forecast EPS upgrades of around 7% longer term.

While the sleep business is likely to remain slightly pressured in the short term due to covid-19 and lower diagnostic rates, mask/accessory re-supply growth will remain robust, assesses the broker.

The Buy rating is unchanged. The target price is increased to $US241 from US$210.

Sector: Health Care Equipment & Services.

 

Current Price is $27.92. Target price not assessed.

 

 

Broker News

About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →